Scientists told a Commons committee that exposure in early life to a bacterial toxin produced by Escherichia coli, called colibactin, is a leading candidate to explain rising rates of bowel cancer among people under 50.
Early-life exposure proposed as factor
During the evidence session, researchers described colibactin as a potential driver of early-onset colorectal cancer, saying that the timing of exposure — potentially in childhood or adolescence — may be important. They told MPs that while established risks such as obesity and reduced physical activity have contributed to the trend, those factors alone do not fully explain the sharp rise in younger patients.
Rising incidence across countries
MPs were reminded that cases of early-onset colorectal cancer have roughly doubled in many countries over the past 20 years. The scientists appearing before the committee emphasized that the upward trend is a cause for concern and suggested that additional environmental, microbial or developmental influences are likely at play alongside lifestyle factors.
Calls for further investigation and public health attention
The experts urged more research to test the hypothesis that colibactin exposure increases long-term colorectal cancer risk and to determine how common such exposure is. They told the committee that confirming a causal link would have implications for surveillance, prevention strategies and future screening policies but that more evidence is required before policy changes are recommended.
Unresolved questions remain
The session highlighted gaps in current understanding, including the pathways by which early microbial exposures might lead to cancer decades later and how to identify individuals at elevated risk. MPs were told that coordinated studies, long-term data collection and collaboration between microbiologists, epidemiologists and public health bodies will be needed to clarify the role of colibactin in early-onset bowel cancer.